compounded glp-1 side effects GLP-1s: Why doctors worry and the FDA is cracking down May 4, 2025: New study
Description
The change, advocates argue, would curb rising obesity rates, reduce health care disparities and save on health care costs.
Orforglipron, Lillys first small-molecule oral GLP-1 receptor agonist in Phase 3, showed meaningful weight loss and glycemic control in adults with type 2 diabetes and overweight or obesity
However, not all weight loss programs are created equal
Editors Note: The following information was provided by the Nottawaseppi Huron Band of the Potawatomi Health Department
Confused about where to start your metabolic health journey
How GLP-1 Receptor Agonists Could Complement MASH Treatment
